Atul share price rose in the early trade on August 12 after the company's subsidiary Atul Bioscience (ABL), received Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its manufacturing facility situated in Ambernath, Maharashtra.
At 9:34am, Atul was quoting at Rs 8064, up Rs 81.85, or 1.03 percent, on the BSE.
The EIR was issued post the last inspection of the facility conducted from May 6 to May 10 which concluded with zero FDA 483 observations.
The company is engaged in manufacturing and marketing of active pharmaceutical ingredients (APIs), their intermediates and contract manufacturing operations.
Catch all market action in our live blog
The company had reported 8.25 percent jump in its June quarter net profit at Rs 111.88 crore versus Rs 103.35 crore in June 2023.
The revenue rose 11.85 percent at Rs 1,322.05 crore from Rs 1,182.02 crore, YoY.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
